RecruitingNCT07148310

Hepatocellular Carcinoma Identification Using Delta-HLD

Proof-of-Concept Case-Control Study for Hepatocellular Carcinoma Identification Using Delta-HLD Technology (HIDE)

Sponsor

Epiliquid Holding, Inc

Enrollment

200 participants

Start Date

May 18, 2023

Study Type

OBSERVATIONAL

Conditions

Hepato Cellular Carcinoma (HCC)

Summary

HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria3

Histologically confirmed HCC (cases) or clinically confirmed liver cirrhosis without HCC (controls)
Willing and able to provide informed consent
Available paired plasma and liver tissue sample

Exclusion Criteria4

Other active cancers
Prior liver transplantation
Known hereditary cancer syndromes
Recent chemotherapy or antiviral treatment (\<3 months)

Locations(1)

Epiliquid

Mendoza, Argentina

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07148310

Related Trials

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

NCT0699065914 locations

Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma

NCT073029193 locations